1. Khemlina G, Ikeda S, Kurzrock R. The biology of Hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer 2017;16:149.

2. Lee DH, Lee JM. Primary malignant tumours in the non-cirrhotic liver. Eur J Radiol 2017;95:349-61.

3. Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, et al. A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 2007;25:107-14.

4. Daruwalla J, Greish K, Nikfarjam M, Millar I, Malcontenti-Wilson C, et al. Evaluation of the effect of SMA-pirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice. J Drug Target 2007;15:487-95.

5. Zou HY, Wu HL, Zhang Y, Li SF, Nie JF, et al. Studying the interaction of pirarubicin with DNA and determining pirarubicin in human urine samples: combining excitation-emission fluorescence matrices with second-order calibration methods. J Fluoresc 2009;19:955-66.

6. Sieghart W, Hucke F, Pinter M, Graziadei I, Vogel W, et al. The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatology 2013;57:2261-73.

7. Georgiades C, Geschwind JF, Harrison N, Hines-Peralta A, Liapi E, et al. Lack of response after initial chemoembolization for hepatocellular carcinoma: does it predict failure of subsequent treatment? Radiology 2012;265:115-23.

8. Li B, Zhu Y, Sun Q, Yu C, Chen L, et al. Reversal of the Warburg effect with DCA in PDGFtreated human PASMC is potentiated by pyruvate dehydrogenase kinase1 inhibition mediated through blocking Akt/GSK3beta signalling. Int J Mol Med 2018;42:1391-400.

9. Peng F, Wang JH, Fan WJ, Meng YT, Li MM, et al. Glycolysis gatekeeper PDK1 reprograms breast cancer stem cells under hypoxia. Oncogene 2018;37:1062-74.

10. Kan PC, Chang YJ, Chien CS, Su CY, Fang HW. Coupling dichloroacetate treatment with curcumin significantly enhances anticancer potential. Anticancer Res 2018;38:6253-61.

11. Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, et al. Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma. Br J Cancer 2013;108:72-81.

12. Li P, Guo P, Lin C, He M, Zhu X, et al. The synergistic effect of propofol and ulinastatin suppressed the viability of the human lung adenocarcinoma epithelial A549 cell line. Oncol Lett 2018;16:5191-9.

13. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.

14. Ni Z, Wang B, Dai X, Ding W, Yang T, et al. HCC cells with high levels of Bcl-2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway. Free Radic Biol Med 2014;70:194-203.

15. Nowak R, Tarasiuk J. Anthraquinone antitumour agents, doxorubicin, pirarubicin and benzoperimidine BP1, trigger caspase-3/caspase-8-dependent apoptosis of leukaemia sensitive HL60 and resistant HL60/VINC and HL60/DOX cells. Anticancer Drugs 2012;23:380-92.

16. Daruwalla J, Nikfarjam M, Greish K, Malcontenti-Wilson C, Muralidharan V, et al. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymer-pirarubicin micelles: Survival improvement and inhibition of liver metastases. Cancer Sci 2010;101:1866-74.

17. Liang YH, Shao YY, Chen JY, Liang PC, Cheng AL, et al. Modern prospection for hepatic arterial infusion chemotherapy in malignancies with liver metastases. Int J Hepatol 2013;2013:141590.

18. Hirakawa M, Nishie A, Asayama Y, Fujita N, Ishigami K, et al. Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of unresectable hepatoblastoma in children. Jpn J Radiol 2014;32:529-36.

19. James MO JS, Zhong G, Smeltz MG, Hu Z, Stacpoole PW. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacol Ther 2017;170:15.

20. Tataranni T, Piccoli C. Dichloroacetate (DCA) and cancer: an overview towards clinical applications. Oxid Med Cell Longev 2019;2019:8201079.

21. Florean C, Song S, Dicato M, Diederich M. Redox biology of regulated cell death in cancer: a focus on necroptosis and ferroptosis. Free Radic Biol Med 2019;134:177-89.

22. Moreno-Caceres J, Fabregat I. Apoptosis in liver carcinogenesis and chemotherapy. Hepat Oncol 2015;2:381-97.

23. Qu X, Sheng J, Shen L, Su J, Xu Y, et al. Autophagy inhibitor chloroquine increases sensitivity to cisplatin in QBC939 cholangiocarcinoma cells by mitochondrial ROS. PLoS One 2017;12:e0173712.

24. Guo XL, Li D, Sun K, Wang J, Liu Y, et al. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma. J Mol Med (Berl) 2013;91:473-83.

25. Mizutani H, Hotta S, Nishimoto A, Ikemura K, Miyazawa D, et al. Pirarubicin, an anthracycline anticancer agent, induces apoptosis through generation of hydrogen peroxide. Anticancer Res 2017;37:6063-9.

26. Dai Y, Xiong X, Huang G, Liu J, Sheng S, et al. Dichloroacetate enhances adriamycin-induced hepatoma cell toxicity in vitro and in vivo by increasing reactive oxygen species levels. PLoS One 2014;9:e92962.

27. Pang Y, Qin G, Wu L, Wang X, Chen T. Artesunate induces ROS-dependent apoptosis via a Bax-mediated intrinsic pathway in Huh-7 and Hep3B cells. Exp Cell Res 2016;347:251-60.

28. Tang Y, Zhang Y, Wang C, Sun Z, Li L, et al. 14-3-3zeta binds to hepatitis B virus protein X and maintains its protein stability in hepatocellular carcinoma cells. Cancer Med 2018;7:5543-53.

29. Fukuhara T, Yamamoto S, Ono C, Nakamura S, Motooka D, et al. Quasispecies of hepatitis C virus participate in cell-specific infectivity. Sci Rep 2017;7:45228.

30. Kambara H, Fukuhara T, Shiokawa M, Ono C, Ohara Y, et al. Establishment of a novel permissive cell line for the propagation of hepatitis C virus by expression of microRNA miR122. J Virol 2012;86:1382-93.

31. Nayak MK, Dhanesha N, Doddapattar P, Rodriguez O, Sonkar VK, et al. Dichloroacetate, an inhibitor of pyruvate dehydrogenase kinases, inhibits platelet aggregation and arterial thrombosis. Blood Adv 2018;2:2029-38.

32. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008;99:6.

33. Khan A, Andrews D, Blackburn AC. Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. World J Clin Cases 2016;4:336-43.

34. Khan A, Andrews D, Blackburn AC. Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. World J Clin Cases 2016;4:8.

35. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117:12.

36. Abdelmalak M, Lew A, Ramezani R, Shroads AL, Coats BS, et al. Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab 2013;109:5.

37. Dhanasekaran DN, Reddy EP. JNK-signaling: a multiplexing hub in programmed cell death. Genes Cancer 2017;8:682-94.

38. Dunnill CJ, Ibraheem K, Mohamed A, Southgate J, Georgopoulos NT. A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis. Oncogene 2017;36:2515-28.

39. Win S, Than TA, Kaplowitz N. The regulation of JNK signaling pathways in cell death through the interplay with mitochondrial SAB and upstream post-translational effects. Int J Mol Sci 2018;19:3657.

40. Stander XX, Stander BA, Joubert AM. Synergistic anticancer potential of dichloroacetate and estradiol analogue exerting their effect via ROS-JNK-Bcl-2-mediated signalling pathways. Cell Physiol Biochem 2015;35:1499-526.

41. Yang X, Zhang H, Wu J, Yin L, Yan LJ, et al. Humanin attenuates NMDA-induced excitotoxicity by inhibiting ROS-dependent JNK/p38 MAPK pathway. Int J Mol Sci 2018;19:2982.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: